RxDoctor Payments Data

Leslie Saland, MD

Neurology · Mount Kisco, NYNPI 1922112416

Payments from drug & device makers

$3,144in general payments, 2019–2025

Across 68 payments — averaging $46.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1K
  • AbbVie$563
  • Novartis$467
  • Genentech USA, Inc.$433
  • Eisai Inc.$125
  • Lilly USA, LLC$125
  • plus $332 from 6 others

What the payments were for

  • Consulting fees$1505%
  • Food & beverage$2,90192%
  • Education$933%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen14$1,099
AbbVie(2 entities)23$563
Novartis16$467
Genentech USA, Inc.5$433
Eisai Inc.1$125
Lilly USA, LLC1$125
Amgen1$115
Argenx US, Inc.1$109
TG Therapeutics, Inc.2$39
EMD Serono, Inc.2$26
Lundbeck LLC1$23
Pfizer1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,144 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$381,213
Medicare patients
246
Services billed
18,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a21$299,367
VumerityDiroximel Fumarate13$117,200
Avonex (4 Pack)Interferon Beta-1a14$113,176
Kesimpta PenOfatumumab12$108,337
Dalfampridine ErDalfampridine68$80,822
AmpyraDalfampridine12$51,992
GlatopaGlatiramer Acetate11$48,472
Nurtec OdtRimegepant Sulfate21$33,669
UbrelvyUbrogepant22$21,210
Lidocaine16$7,233
Gabapentin145$4,041
Sumatriptan Succinate90$3,513
Baclofen122$2,921
Duloxetine Hcl67$2,080
Carbamazepine26$2,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Avonex (4 Pack)$1,099$230,37627 claims
PfizerNurtec Odt$20$33,66921 claims
AbbVieUbrelvy$563$21,21022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.

Other neurology in Mount Kisco

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →